In conclusion, akiferidin exerts potent anti-cervical cancer activity by inhibiting angiogenesis through modulation of the VEGF/DLL4-Notch pathway, and its combination with bevacizumab enhances antitumor efficacy with favorable <i>in vivo</i> safety, representing a promising therapeutic strategy for cervical cancer. This evidence concerns the gene DLL4 and cervical carcinoma.